nausea and vomitting. Nausea and vomiting
Conditions
Interventions
Intervention 1: group1: Ondancetron ampule 4mg intravenous after anesthetic induction and placebo capsule 1 hour before operation. Intervention 2: group 2: Aprepitant capsule 80mg 1 hour before operat
Treatment - Drugs
group1: Ondancetron ampule 4mg intravenous after anesthetic induction and placebo capsule 1 hour before operation
group 2: Aprepitant capsule 80mg 1 hour before operation and placebo ampule (normal saline) after anesthetic induction is administered
group 3: Aprepitant capsule 80mg 1 hour before operation and Ondansetron 4mg intravenous after anesthetic induction is administered
Sponsors
Vice President of Research, Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women between 18 to 50 years old with ASA class 1 and 2 with at least 2 criteria of APFEL (female; nonsmoker; motion sickness or PONV history; using opioids 100mcg fentanyl or equivalent ) Exclusion criteria: women under 18 or greater than 50 years old; AA class 3 or more; cholecystectomy in other anesthesia; systemic disease like diabetes; asthma; cardiovascular; reflux, severe obesity; pregnancy; breast feeding; hepatic and renal disease; neuromuscular disease; psychotic disease; addiction; acute cholecystitis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea and vomitting. Timepoint: 6 and 24 hours after operation. Method of measurement: VAS criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization period. Timepoint: at discharge time. Method of measurement: hospitalization days. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Karami
Besat Hospital, Kurdistan University of Medical Sciences
Outcome results
None listed